share_log

UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

瑞银维持对Apellis Pharmicals的买入,将目标股价下调至85美元
Benzinga ·  05/08 09:14

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to $85.

瑞银分析师埃利安娜·梅尔维持Apellis Pharmicals(纳斯达克股票代码:APLS)的买入并将目标股价从89美元下调至85美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发